Please try another search
For the six months ended 30 June 2016, Raptor Pharmaceutical Corp. revenues increased 36% to $59.5M. Net loss increased 65% to $55.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects General and administrative increase of 40% to $37.4M (expense), Research and development increase of 5% to $28.5M (expense).
Period Ending: | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 |
---|---|---|---|---|
Total Revenue | 32.05 | 27.47 | 24.67 | 25.79 |
Gross Profit | 27.1 | 23.14 | 21.04 | 23.16 |
Operating Income | -9.45 | -36.14 | -13.66 | -11.18 |
Net Income | -14.02 | -41.59 | -17 | -14.59 |
Period Ending: | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 |
---|---|---|---|---|
Total Assets | 354.94 | 363.97 | 419.49 | 251.55 |
Total Liabilities | 287.25 | 285.62 | 302.3 | 140.85 |
Total Equity | 67.69 | 78.35 | 117.19 | 110.7 |
Period Ending: | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 |
---|---|---|---|---|
Period Length: | 6 Months | 3 Months | 12 Months | 9 Months |
Cash From Operating Activities | -27.05 | -21.93 | -44.16 | -31.88 |
Cash From Investing Activities | -0.89 | -0.62 | -37.77 | -2.42 |
Cash From Financing Activities | -5.28 | -2.96 | 90.9 | 93.08 |
Net Change in Cash | -33.11 | -25.31 | 7.74 | 58.03 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review